CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

NCT05420493 ·Status: RECRUITING ·Phase: PHASE1

Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma

NCT05478343 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

CAR-T for R/R B-NHL

NCT03196830 ·Status: UNKNOWN ·Phase: PHASE2

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

NCT04089215 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

NCT05745181 ·Status: RECRUITING ·Phase: PHASE2

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

NCT05618041 ·Status: RECRUITING ·Phase: NA

CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

NCT03121625 ·Status: UNKNOWN ·Phase: PHASE1

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

NCT04973527 ·Status: TERMINATED ·Phase: PHASE1

Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies

NCT05127135 ·Status: UNKNOWN ·Phase: PHASE1

CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma

NCT06850285 ·Status: RECRUITING ·Phase: NA

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

NCT04665063 ·Status: UNKNOWN ·Phase: NA

Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL

NCT05554575 ·Status: UNKNOWN ·Phase: PHASE1

Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

NCT06633341 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma

NCT04537442 ·Status: UNKNOWN ·Phase: PHASE1

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

NCT04718883 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

NCT06238336 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma

NCT06532643 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

NCT06381830 ·Status: RECRUITING ·Phase: PHASE2

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

NCT02541370 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

CART-19 Immunotherapy in Mantle Cell Lymphoma

NCT02081937 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

NCT03488160 ·Status: UNKNOWN ·Phase: NA

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies

NCT06758713 ·Status: RECRUITING ·Phase: PHASE1

A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

NCT06783816 ·Status: RECRUITING ·Phase: NA

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

NCT06911710 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

NCT05106907 ·Status: UNKNOWN ·Phase: PHASE1